CINGW icon

Cingulate Inc. Warrants

0.0392 USD
Updated May 22, 10:29 AM EDT
1 day
0.00%
5 days
5.38%
1 month
-12.89%
3 months
20.62%
6 months
-5.08%
Year to date
-35.42%
1 year
223.97%
5 years
-96.08%
10 years
-96.08%
 

About: Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Employees: 13

0
Funds holding %
of 7,245 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

25% more funds holding

Funds holding: 4 [Q4 2024] → 5 (+1) [Q1 2025]

0.29% more ownership

Funds ownership: 7.57% [Q4 2024] → 7.86% (+0.29%) [Q1 2025]

21% less capital invested

Capital invested by funds: $17.7K [Q4 2024] → $14.1K (-$3.63K) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Research analyst outlook

We haven’t received any recent analyst ratings for CINGW.

Financial journalist opinion

We haven’t received any recent news articles for CINGW.

Charts implemented using Lightweight Charts™